Florida

Back to map

Showing 11-20 of 24 grants

Title Institution Researcher Program Duration Total Award Amount
Enhance β-Cell Replacement Therapies via Localized Immune Modulation Using DIANA Nanocarriers University of Miami Peter Buchwald Cures 01-September-2023 to 31-August-2026 $900.000,00
Network for Pancreatic Organ Donors – nPOD University of Florida Mark Atkinson Cures 01-October-2023 to 30-September-2026 $8.100.000,00
mIL-2/CD25 fusion protein and BTK inhibitor combination therapy for T1D University of Miami Wasif Khan Cures 01-May-2023 to 30-April-2026 $974.996,00
Modulate beta cell proliferation and immunogenicity via aptamer-decorated lipid nanoparticles University of Miami Paolo Serafini Cures 01-April-2023 to 31-March-2026 $894.602,00
Tolerance signals from human pregnancy for beta cell replacement therapy University of Florida Edward Phelps Cures 01-December-2023 to 30-November-2025 $600.000,00
Transdisciplinary Care for Young Adults with Type 1 Diabetes Transitioning to Adult Healthcare Nemours Children's Clinic Jessica Pierce Improving Lives 01-May-2023 to 30-April-2026 $628.819,87
A Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat (Xiflam) for Diabetic Macular Edema Jaeb Center for Health Research Adam Glassman Improving Lives 01-September-2022 to 01-January-2026 $273.424,00
Repurposing Cardiorenal Drugs for T1D: Building Evidence from Existing Trials (ReCaRD T1D) AdventHealth Richard Pratley Improving Lives 01-September-2023 to 31-August-2025 $110.840,00
Deep Learning-based Analyses of Pancreatic Islet Beta-Cell Heterogeneity and MRI Pancreas Volume as Biomarkers to Improve Understanding of Type 1 Diabetes Progression University of Florida Sarah Kim Cures 01-June-2022 to 31-May-2026 $750.000,00
Advanced Preclinical Development of iTOL-101, a Combination Investigational Product Composed of A Biotechnology-Derived Chimeric Streptavidin and A Fas Ligand (SA-FasL) Protein Bound to Biotinylated Hydrogel-Based Microparticles (Microgel) and Mixed with Deceased Donor Human Pancreatic Islets for the Treatment of Poorly-Controlled (or “Brittle”) Type 1 Diabetes iTolerance, Inc. Camillo Ricordi Cures 01-June-2022 to 31-August-2025 $850.000,00